pirenzepine has been researched along with Pancreatic Insufficiency in 1 studies
Pirenzepine: An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| von Kleist, D | 1 |
| Rössler, W | 1 |
| Janisch, HD | 1 |
| Hampel, KE | 1 |
1 trial available for pirenzepine and Pancreatic Insufficiency
| Article | Year |
|---|---|
[The diagnostic value of serum PABA determination in pancreatic disease and in relation to anticholinergic medication].
Topics: 4-Aminobenzoic Acid; Adult; Cholecystokinin; Dose-Response Relationship, Drug; Exocrine Pancreatic I | 1989 |